Oncolytics Biotech Completes Domicile Change to the United States

San Diego, CA, April 1, 2026 – Oncolytics Biotech Inc. (Nasdaq: ONCY), a clinical-stage immunotherapy company focused on developing pelareorep, has announced the official completion of its previously disclosed plan to change its jurisdiction of incorporation from Canada to the United States.

Key Highlights

• Corporate Domicile Change: Oncolytics transitioned its legal domicile from the Province of Alberta, Canada, to the State of Nevada, USA. This process involved an interim continuation through British Columbia, finalized on March 31, 2026.
• New Headquarters: The company’s San Diego office has become its new headquarters, though it will retain its Calgary office as well.
• Approval and Process: Shareholders approved the move at a Special Meeting on January 15, 2026. The change became effective following filings with Nevada authorities.
• Ticker and Trading: Oncolytics’ common stock will continue to trade on Nasdaq under the ticker “ONCY”. Effective today, its new CUSIP is 68237V 103 and the ISIN is US68237V1035.
• Majority U.S. Focus: Most investors, management, and capital markets activity are now U.S.-based, making this move strategically significant.

Potentially Price-Sensitive Information for Shareholders

• Operational Efficiency and Regulatory Streamlining: The company expects the U.S. domicile will provide greater operational efficiency, a more streamlined regulatory structure, and improved access to U.S. capital markets. These factors could be highly material for investor perception and future capital raising efforts.
• Legal Environment: Management cited Nevada’s favorable corporate legal environment for biotech companies as a key reason for the move, suggesting potential benefits in governance and regulatory flexibility.
• Loss of Foreign Private Issuer Status: Oncolytics no longer qualifies as a “foreign private issuer” under U.S. securities laws. This could impact regulatory reporting requirements and investor relations, potentially increasing the company’s visibility and credibility among U.S. institutional investors.

Business Update and Pipeline Progress

Oncolytics is advancing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent. Key points regarding the pipeline:

• Pelareorep has shown encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 trials in metastatic breast cancer, and early-phase studies in anal and colorectal cancer.
• The drug is designed to convert immunologically “cold” tumors “hot” by activating innate and adaptive immune responses, aiming to enhance anti-cancer effects.
• Pelareorep is being developed in combination with chemotherapy and/or checkpoint inhibitors for metastatic gastrointestinal cancers.
• The therapy has received Fast Track designation from the FDA for both colorectal and pancreatic cancer, signaling regulatory support and potential expedited pathways.
• Oncolytics is actively seeking strategic partnerships to accelerate development and maximize commercial impact, which could provide future catalysts for the stock.

Management Commentary

CEO Jared Kelly emphasized that the decision to domesticate in the U.S. reflects the company’s operational realities and strategic focus on U.S. markets. He stated, “As we no longer qualified as a ‘foreign private issuer’ under applicable U.S. securities laws, it made sense to overhaul our corporate structure and change Oncolytics’ jurisdiction of incorporation to reflect its status as a U.S. domestic issuer.” He added that the new structure is expected to streamline execution of company goals and create long-term value for shareholders.

Forward-Looking Statements and Risks

The company cautions that forward-looking statements are subject to risks and uncertainties, including regulatory outcomes, trial execution, financial resources, access to capital markets, and broader market dynamics. Investors should review the company’s annual report and public filings for a comprehensive discussion of these risks.

Contact Information

For further inquiries, investors can contact Jon Patton, Director of IR & Communication, at [email protected].

Disclaimer

This article is provided for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. Investors should conduct their own due diligence before making investment decisions, including reviewing official company filings and consulting with a qualified financial advisor.

View ONCOLYTICS BIOTECH INC Historical chart here